Regulators outline actions to oversee drug firms' claims

FDA, SEC would share information

By Ross Kerber

Globe Staff / February 6, 2004

E-mail|
Print|
Reprints|
|

Text size – +

Drug and securities regulators in Washington yesterday outlined steps to ensure companies tell the truth about their dealings with the government, following complaints of improper disclosure by ImClone Systems Inc. and other biotechnology companies. (Full Article: 587 Words)